Abstract
Abstract The management of early-stage triple-negative (TN) and HER2-positive (HER2+) breast cancer has evolved significantly with continually improving systemic therapies. The use of neoadjuvant chemotherapy (NAC) has become standard for stage II disease, for both surgical downstaging and assessment of response to treatment, allowing for tailoring of systemic therapy in the adjuvant setting. However, the optimal treatment approach for stage I TN and HER2+ disease remains controversial, given the limited burden of disease at presentation with most patients considered candidates for limited surgery, and the excellent overall outcomes with de-escalated systemic therapy regimens in the adjuvant setting. This presentation will discuss the evolving landscape and current standards for stage I TN and HER2+ disease. Citation Format: A. Mamtani. Surgical management of Stage I TN and HER2+ breast cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr ED05-03.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
